Business Description
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
Business History
Price Overview
Last updated: Jun 27, 2026 9:54am (9m ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -5.07
Total Equity: $415.19M
Shares: 114,208,000
Total Debt: $970.54M
Cash: $151.86M
EBITDA: -$361.31M
Total Debt: $970.54M
Cash: $151.86M
Revenue: $1.88B
Shares: 114,208,000
Revenue: $1.88B
Revenue: $1.88B
Revenue: $1.88B
Total Equity: $415.19M
Tax Rate: 0.0%
Equity: $415.19M
Total Debt: $970.54M
Cash: $151.86M
Current Liabilities: $385.26M
Long-Term Debt: $970.54M
Total Debt: $970.54M
Total Equity: $415.19M
Shares: 114,208,000
Shares: 114,208,000
CapEx: -$34.09M
Shares: 114,208,000
Stock Price: $5.51
Net Income: -$534.51M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 27, 2026 9:54am (9m ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $908.0M | $1.4B | $2.0B | $2.6B | $1.9B |
| Cost of Revenue | $657.6M | $1.0B | $1.5B | $2.2B | $1.6B |
| Gross Profit | $250.4M | $316.6M | $460.5M | $367.4M | $284.0M |
| Operating Expenses | $292.8M | $312.9M | $531.7M | $407.8M | $288.5M |
| Operating Income | -$42.4M | $3.6M | -$71.2M | -$40.5M | -$4.4M |
| Net Income | -$37.6M | -$19.2M | -$113.0M | -$61.6M | -$534.5M |
| EBITDA | $55.7M | $43.7M | -$24.8M | $84.9M | -$361.3M |
| EPS | $-0.36 | $-0.20 | $-1.28 | $-0.81 | $-5.07 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 9:54am (9m ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $266.3M | $188.2M | $192.8M | $104.2M | $151.9M |
| Total Current Assets | $524.0M | $478.1M | $683.7M | $607.1M | $506.4M |
| Total Assets | $1.4B | $1.8B | $2.7B | $2.5B | $1.9B |
| Current Liabilities | $445.5M | $433.4M | $674.2M | $715.5M | $385.3M |
| Long-Term Debt | $215.7M | $413.0M | $597.0M | $490.5M | $970.5M |
| Total Liabilities | $725.8M | $957.9M | $1.6B | $1.5B | $1.5B |
| Total Equity | $693.6M | $859.4M | $1.1B | $1.0B | $415.2M |
| Retained Earnings | -$626.8M | -$606.2M | -$719.2M | -$780.8M | -$1.3B |
Cash Flow (Annual)
Last updated: Jun 27, 2026 9:54am (9m ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $38.7M | -$11.6M | $142.6M | $18.8M | $38.8M |
| Capital Expenditure | -$25.0M | -$38.4M | -$28.7M | -$24.9M | -$34.1M |
| Free Cash Flow | $13.8M | -$49.9M | $113.8M | -$6.1M | $4.8M |
| Acquisitions (net) | $14.2M | $5.6M | $870,000 | -$30.7M | -$57.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$40.0M |
| Net Change in Cash | -$6.6M | -$139.8M | $8.3M | -$45.0M | $14.5M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:54am (9m ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$3.0B $2.7B – $3.2B
|
$3.4B $3.4B – $3.4B
|
$4.1B $3.9B – $4.3B
|
$4.7B $4.4B – $4.9B
|
| EBITDA |
-$46.4M -$49.9M – -$42.4M
|
-$52.9M -$52.9M – -$52.9M
|
-$64.2M -$67.4M – -$60.6M
|
-$72.9M -$76.7M – -$68.8M
|
| Net Income |
$41.3M $39.8M – $42.7M
|
$49.7M -$18.0M – $117.5M
|
$79.9M $74.1M – $85.3M
|
$94.8M $87.9M – $101.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 9:54am (9m ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +48.9% | +45.3% | +30.1% | -26.6% |
| Gross Profit Growth | +26.4% | +45.4% | -20.2% | -22.7% |
| Operating Income Growth | +108.6% | -2,055.3% | +43.1% | +89.0% |
| Net Income Growth | +49.0% | -489.9% | +45.5% | -767.4% |
| EBITDA Growth | -21.4% | -156.7% | +442.4% | -525.8% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 9:54am (9m ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-04 | Ajayi Toyin | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | Glass Russell Monroe | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | GRUA PETER J | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | GUERTIN SHAWN M | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | Jelinek Richard M | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | KECK KIM | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | Smith Jill D. | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | Springstubb Brendan B | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-06-04 | Barbarosh Craig A. | A-Award | 41,096.00 | $0.00 | $0 |
| 2026-03-02 | Blackley Seth | A-Award | 1,425,310.00 | $0.00 | $0 |
| 2026-03-02 | Blackley Seth | A-Award | 58,921.00 | $0.00 | $0 |
| 2026-03-02 | Blackley Seth | F-InKind | 17,736.00 | $3.58 | $63,495 |
| 2026-03-03 | Blackley Seth | F-InKind | 24,053.00 | $3.51 | $84,426 |
| 2026-03-01 | Blackley Seth | F-InKind | 9,537.00 | $3.25 | $30,995 |
| 2026-03-02 | Weinberg Jonathan | A-Award | 4,910.00 | $0.00 | $0 |
| 2026-03-02 | Weinberg Jonathan | F-InKind | 1,896.00 | $3.58 | $6,788 |
| 2026-03-01 | Weinberg Jonathan | F-InKind | 4,406.00 | $3.25 | $14,320 |
| 2026-03-03 | Weinberg Jonathan | F-InKind | 8,275.00 | $3.51 | $29,045 |
| 2026-03-02 | Weinberg Jonathan | A-Award | 179,661.00 | $0.00 | $0 |
| 2026-03-02 | McCarthy Daniel Joseph | A-Award | 826,440.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).